Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced that it has entered into two strategic collaborations with the Ragon Institute of MGH, MIT and Harvard to investigate the ...
Read More »Codiak presents new preclinical data demonstrating potential of engEx™ engineered exosomes to drive new class of molecular medicines
Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced new preclinical...
Read More »Microfluidic on-demand engineering of exosomes towards cancer immunotherapy
Extracellular Vesicles (EVs), particularly exosomes (30-150 nm), are an emerging delivery system in mediating cellular communications, which have been observed for priming immune responses by presenting parent cell signaling proteins or tumor antigens...
Read More »Therapeutic potential of engineered extracellular vesicles
Extracellular vesicles (EVs) comprise a heterogeneous group of small membrane vesicles, including exosomes, which play a critical role in intracellular communication and regulation of numerous physiological processes in health and disease. Naturally released from virtually all cells, these vesicles contain ...
Read More »